Greater tumor-infiltrating lymphocyte density is associated with improved overall survival outcomes in patients with ...

In its 10-K report, Iovance Biotherapeutics highlighted its commercialization efforts for Amtagvi, the first product within ...

Higher TIL levels predict better survival in early ERBB2-positive breast cancer, supporting treatment de-escalation for ...

Rather, TIL have made a decisive move toward an in-licensing strategy, bringing in a bispecific antibody called SYN-2510.

Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue Guidance of $450M-$475M ...

Although it reported 2024 Q4 and full-year results that beat expectations and reiterated 2025 guidance that includes ...

近年来，随着创新药物的迅猛发展，肿瘤免疫治疗的疗效和安全性已经获得了临床医生和科研人员广泛的认可与接纳。肿瘤浸润淋巴细胞（tumor-infiltrating lymphocytes，TILs）是指浸润到肿瘤组织中的淋巴细胞，包括 T 细胞和 B ...

Iovance Biotherapeutics, Inc.’s IOVA share price has dipped by 19.49%, which has investors questioning if this is right time ...

AbbVie, Thermo Fisher Scientific, Recursion Pharmaceuticals, Bloom Energy, and Iovance Biotherapeutics are the five Biotech ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.38, a high estimate of $32.00, and a low estimate of $6.00. Highlighting a 10.88% decrease, the current ...

U.S. stocks staged a comeback on Friday, with the S&P 500 surging 1.59% and reversing a sharp sell-off driven by fears that ...

New York State Common Retirement Fund trimmed its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free ...